Trial
NCT00738699
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Morphotek
Collaborators
—
Condition
Ovarian Cancer
Intervention
MORAb-003 (farletuzumab)
Why stopped
study did not meet pre-specified criteria for continuation following interim futility analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-30